LION Bioscience might become king of summer's IPOs

Article Abstract:

This article describes the rush in Europe to invest in biotechnology companies. While MediGene, GeneScan Europe, Curasan and Modex Therapeutics are among the most popular new companies, LION Bioscience, which plans to issue 4.57 million shares, could be the biggest biotech IPO in Europe this summer.

United States, Biochemistry, Switzerland, Organizational history, Statistical Data Included, Finance, Brief Article, LION bioscience AG, MediGene AG, GeneScan Europe AG, Curasan AG, Modex Therapeutics Ltd.

---

Germany's bitter ethics debate

Article Abstract:

In Germany, a contentious ethical debate has arisen over the utilization of human embryos in research. The debate is being carried out within the context of Germany's Nazi past and the country's biotechnology future.

Science & research, Public affairs, Cellular Biology, Research, Ethical aspects, Cytology, Stem cells, Human embryo

---

Bayer emerges as front-runner for Aventis unit

Article Abstract:

Bayer AG has become the leading contender to acquire Aventis SA's CropScience unit. The unit is valued at approximately $3 billion (3.55 billion euros).

Strategy & planning, France, Genetic Engineering, Planning, Bayer AG, Aventis S.A., Aventis CropScience S.A., BAYZY, AVE

Similar abstracts:

• Abstracts: J.P. Morgan Chase saw net income decline in quarter. Banks' 2nd-quarter results disappoint. Enron secures $1.5 billion in financing from creditors
• Abstracts: ICI sells some businesses to Huntsman. Colt's agrees to acquire Germany's Heckler & Koch. Tomkins to sell Smith & Wesson to Saf-T-Hammer for $15 million
• Abstracts: Knight Ridder plans reduction of jobs at most papers. USG's shares soar after firm files for protection. CareerBuilder to buy rival site for $200 million
• Abstracts: U.S. rejects linking of plane orders to software sanctions. Worldspan to enter China in linkup with travel Web site
• Abstracts: Gucci's 1st-quarter profit comes in short of estimates. Hermes beats expectations with 38% increase in profit

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.